Print Friendly, PDF & Email

NCT/Study#

NCT04150965 /

MMRC-089

A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207)

DISEASE GROUP:

Multiple Myeloma

current phase:

Phase I/II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587